Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 1994-2003

  Werner, Lauryn R ^a   Huang, Shyhmin ^a   Francis, David M ^a   Armstrong, Eric A ^a   Ma, Fang ^a   Li, Chunrong ^a   Iyer, Gopal ^a   Canon, Jude ^b   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 232; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DAMAGE REGULATED AUTOPHAGY MODULATOR PROTEIN; DNA; GAMMAH2AX PROTEIN; HISTONE H2AX; PEPTIDES AND PROTEINS; PROTEIN BAX; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; RADIOSENSITIZING AGENT; SMALL MOLECULE TRANSPORT AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; ULK 1 PROTEIN; UNCLASSIFIED DRUG; 2-(5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-(1-(ISOPROPYLSULFONYL)-3-METHYLBUTAN-2-YL)-3-METHYL-2-OXOPIPERIDIN-3-YL)ACETIC ACID; ACETIC ACID DERIVATIVE; PIPERIDONE DERIVATIVE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL AGING; CELL PROLIFERATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; IONIZING RADIATION; METABOLISM; NEOPLASMS; RADIATION TOLERANCE;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; PIPERIDONES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942110856     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1056-T     Document Type: Article

References (43)

1. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014;13:217-36.
2. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin J-L, Espinosa JnM. The p53 circuit board. BBA-Rev Cancer 2012;1825:229-44.
3. Fahraeus R, Olivares-Illana V. Mdm2's social network. Oncogene 2014;33:4365-76.
4. Selivanova G. Wild type p53 reactivation: from lab bench to clinic. FEBS Lett 2014;588:2628-38.
5. Klein C, Vassilev LT. Targeting the p53-mdm2 interaction to treat cancer. Br J Cancer 2004;91:1415-9.
6. Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the mdm2-p53 protein-protein interaction (mdm2 inhibitors) in clinical trials for cancer treatment. J Med Chem 2015;58:1038-52.
7. Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, et al. Discovery of amg 232, a potent, selective, and orally bioavailable mdm2-p53 inhibitor in clinical development. J Med Chem 2014;57:1454-72.
8. Rew Y, Sun D. Discovery of a small molecule mdm2 inhibitor (amg 232) for treating cancer. J Med Chem 2014;57:6332-41.
9. Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, et al. The mdm2 inhibitor amg 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther 2015;14:649-58.
10. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM. Mdm2 binds to nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 2005;280:18771-81.
11. Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, et al. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 2013;105:686-93.
12. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 um-scc head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417-26.
13. Huang X, Darzynkiewicz Z. Cytometric assessment of histone h2ax phosphorylation: a reporter of DNA damage. Methods Mol Biol 2006;314:73-80.
14. Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, et al. Autophagy stimulates apoptosis in her2-overexpressing breast cancers treated by lapatinib. J Cell Biochem 2013;114:2643-53.
15. Benavente S, Huang S, Armstrong EA, Chi A, Hsu K-T, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009;15:1585-92.
16. Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A. Jc-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis 2012;3:e430.
17. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, et al. Selective and potent raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010;9:2399-410.
18. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 2004;6:168-70.
19. Barsotti AM, Prives C. Pro-proliferative foxm1 is a target of p53-mediated repression. Oncogene 2009;28:4295-305.
20. Wong PM, Puente C, Ganley IG, Jiang X. The ulk1 complex: sensing nutrient signals for autophagy activation. Autophagy 2013;9:124-37.
21. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, et al. Dram, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-34.
22. Chen Y, Azad MB, Gibson SB. Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol 2010;88:285-95.
23. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009;15:5308-16.
24. Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 2009;14:376-91.
25. Salido M, Gonzalez JL, Vilches J. Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in pc-3 prostate carcinoma cells. Mol Cancer Ther 2007;6:1292-9.
26. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007;6:595-605.
27. Luo H, Yount C, Lang H, Yang A, Riemer EC, Lyons K, et al. Activation of p53 with nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence. Lung Cancer 2013;81:167-73.
28. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102:1536-46.
29. Olive PL. Retention of gammah2ax foci as an indication of lethal DNA damage. Radiother Oncol 2011;101:18-23.
30. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammah2ax foci as an indication of lethal DNA lesions. BMC Cancer 2010;10:4.
31. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 2011;82:427-34.
32. Macintosh RL, Ryan KM. Autophagy in tumour cell death. Semin Cancer Biol 2013;23:344-51.
33. Giansanti V, Torriglia A, Scovassi AI. Conversation between apoptosis and autophagy: "Is it your turn or mine?". Apoptosis 2011;16:321-33.
34. Kenzelmann Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA, et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 2013;27:1016-31.
35. Xiong J, Yang Q, Li J, Zhou S. Effects of mdm2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. Angiogenesis 2014;17:37-50.
36. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37.
37. Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012;15:173-82.
38. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
39. Valentine JM, Kumar S, Moumen A. A p53-independent role for the mdm2 antagonist nutlin-3 in DNA damage response initiation. BMC Cancer 2011;11:79.
40. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993-9.
41. Halasi M, Gartel AL. Suppression of foxm1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS ONE 2012;7:e31761.
42. Wang Z, Zheng Y, Park HJ, Li J, Carr JR, Chen YJ, et al. Targeting foxm1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther 2013;12:759-67.
43. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor foxm1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005;65:5181-9.